Current Diabetes Reports

, Volume 13, Issue 3, pp 435–444 | Cite as

Diabetes Mellitus and Inflammation

  • Eric Lontchi-Yimagou
  • Eugene Sobngwi
  • Tandi E. Matsha
  • Andre Pascal KengneEmail author
Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)


Type 2 diabetes mellitus (T2DM) is increasingly common worldwide. Related complications account for increased morbidity and mortality, and enormous healthcare spending. Knowledge of the pathophysiological derangements involved in the occurrence of diabetes and related complications is critical for successful prevention and control solutions. Epidemiologic studies have established an association between inflammatory biomarkers and the occurrence of T2DM and complications. Adipose tissue appears to be a major site of production of those inflammatory biomarkers, as a result of the cross-talk between adipose cells, macrophages, and other immune cells that infiltrate the expanding adipose tissue. The triggering mechanisms of the inflammation in T2DM are still ill-understood. Inflammatory response likely contributes to T2DM occurrence by causing insulin resistance, and is in turn intensified in the presence of hyperglycemia to promote long-term complications of diabetes. Targeting inflammatory pathways could possibly be a component of the strategies to prevent and control diabetes and related complications.


Diabetes mellitus Inflammation Biomarkers Adipocytes Cytokines Adipokines Interleukin 


Conflict of Interest

Eric Lontchi-Yimagou declares that he has no conflict of interest.

Eugene Sobngwi declares that he has no conflict of interest.

Tandi E Matsha declares that she has no conflict of interest.

Andre Pascal Kengne declares that he has no conflict of interest.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    International Diabetes Federation. In: Unwin N, Whiting D, Guariguata L, Ghyoot G, Gan D, editors. Updated Diabetes Atlas 2011. 5th ed. Brussels; 2011.Google Scholar
  2. 2.
    Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793–801.PubMedCrossRefGoogle Scholar
  3. 3.
    Bending D, Zaccone P, Cooke A. Inflammation and type one diabetes. Int Immunol. 2012;24:339–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Ebstein W. Invited comment on W. Ebstein: on the therapy of diabetes mellitus, in particular on the application of sodium salicylate. J Mol Med. 2002;80:618. discussion 19.PubMedCrossRefGoogle Scholar
  5. 5.
    Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J. 1901;1:760–2.PubMedCrossRefGoogle Scholar
  6. 6.
    Reid J, Macdougall AI, Andrew MM. On the efficacy of salicylates in treating diabetes mellitus. Br Med J. 1957;2:1071–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Shulman GI. Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology. 2004;19:183–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Marques-Vidal P, Schmid R, Bochud M, et al. Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. The CoLaus Study. PLoS One. 2012;7:e51768.PubMedCrossRefGoogle Scholar
  10. 10.
    Goldfine AB, Fonseca V, Shoelson SE. Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem. 2011;57:162–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Kengne AP, Batty GD, Hamer M, et al. Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from 4 U.K. prospective cohort studies. Diabetes Care. 2012;35:396–403.PubMedCrossRefGoogle Scholar
  12. 12.
    Kengne AP, Czernichow S, Stamatakis E, et al. Fibrinogen and future cardiovascular disease in people with diabetes: aetiological associations and risk prediction using individual participant data from 9 community-based prospective cohort studies. Diabetes Vasc Dis Res. 2012.Google Scholar
  13. 13.
    Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. 2012;8:709–16.PubMedCrossRefGoogle Scholar
  15. 15.
    Nikolajczyk BS, Jagannathan-Bogdan M, Shin H, Gyurko R. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun. 2011;12:239–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Donath MY, Schumann DM, Faulenbach M, et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care. 2008;31 Suppl 2:S161–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol. 2012;167:40–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology. 2009;24:325–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Kiechl S, Wittmann J, Giaccari A, et al. Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med. 2013. doi: 10.1038/nm.3084
  20. 20.
    Cai D. Neuroinflammation in overnutrition-induced diseases. Vitam Horm. 2013;91:195–218.PubMedGoogle Scholar
  21. 21.
    Varma V, Yao-Borengasser A, Rasouli N, et al. Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am J Physiol Endocrinol Metab. 2009;296:E1300–10.PubMedCrossRefGoogle Scholar
  22. 22.
    Strissel KJ, Stancheva Z, Miyoshi H, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007;56:2910–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Gealekman O, Guseva N, Hartigan C, et al. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation. 2011;123:186–94.PubMedCrossRefGoogle Scholar
  24. 24.
    Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev. 2013;93:1–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Ye J. Hypoxia in obesity—from bench to bedside. J Transl Med. 2012;10 Suppl 2:A20.CrossRefGoogle Scholar
  26. 26.
    Goossens GH, Bizzarri A, Venteclef N, et al. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation. 2011;124:67–76.PubMedCrossRefGoogle Scholar
  27. 27.
    Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.PubMedGoogle Scholar
  29. 29.
    Blasco-Baque V, Serino M, Vergnes JN, et al. High-fat diet induces periodontitis in mice through lipopolysaccharides (LPS) receptor signaling: protective action of estrogens. PLoS One. 2012;7:e48220.PubMedCrossRefGoogle Scholar
  30. 30.
    Amar J, Chabo C, Waget A, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med. 2011;3:559–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Ebbesson SO, Tejero ME, Lopez-Alvarenga JC, et al. Individual saturated fatty acids are associated with different components of insulin resistance and glucose metabolism: the GOCADAN study. Int J Circumpolar Health. 2010;69:344–51.PubMedGoogle Scholar
  32. 32.
    Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–98.PubMedCrossRefGoogle Scholar
  33. 33.
    Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol. 2011;7:738–48.PubMedCrossRefGoogle Scholar
  34. 34.
    Gurav AN. Periodontitis and insulin resistance: casual or causal relationship? Diabetes Metab J. 2012;36:404–11.PubMedCrossRefGoogle Scholar
  35. 35.
    Pradhan S, Goel K. Interrelationship between diabetes and periodontitis: a review. J Nepal Med Assoc. 2011;51:144–53.Google Scholar
  36. 36.
    Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268–73.PubMedCrossRefGoogle Scholar
  38. 38.
    • Burcelin R, Garidou L, Pomie C. Immuno-microbiota cross and talk: the new paradigm of metabolic diseases. Semin Immunol. 2012;24:67–74. The evidence linking gut microbiota with diabetes occurence are summarized and discussed, including the role of inflammation.PubMedCrossRefGoogle Scholar
  39. 39.
    Rajagopalan S, Brook RD. Air pollution and type 2 diabetes: mechanistic insights. Diabetes. 2012;61:3037–45.PubMedCrossRefGoogle Scholar
  40. 40.
    Andersen ZJ, Raaschou-Nielsen O, Ketzel M, et al. Diabetes incidence and long-term exposure to air pollution: a cohort study. Diabetes Care. 2012;35:92–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Liu C, Ying Z, Harkema J, et al. Epidemiological and experimental links between air pollution and type 2 diabetes. Toxicol Pathol. 2012. doi: 10.1177/0192623312464531
  42. 42.
    Khan H, Kunutsor S, Franco OH, Chowdhury R. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. Proc Nutr Soc. 2013;72:89–97.Google Scholar
  43. 43.
    Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr. 2011;65:1005–15.PubMedCrossRefGoogle Scholar
  44. 44.
    • Sung CC, Liao MT, Lu KC, Wu CC. Role of vitamin D in insulin resistance. J Biomed Biotechnol. 2012;2012:634195. This paper discussed the inflammatory mediators of insulin resistance caused by vitamin D deficiency.PubMedGoogle Scholar
  45. 45.
    Chagas CE, Borges MC, Martini LA, Rogero MM. Focus on vitamin D, inflammation and type 2 diabetes. Nutrients. 2012;4:52–67.PubMedCrossRefGoogle Scholar
  46. 46.
    Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex-linking immunity and metabolism. Nat Rev Endocrinol. 2012;8:743–54.PubMedCrossRefGoogle Scholar
  47. 47.
    Grimble RF. The true cost of in-patient obesity: impact of obesity on inflammatory stress and morbidity. Proc Nutr Soc. 2010;69:511–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Cruz NG, Sousa LP, Sousa MO, et al. The linkage between inflammation and Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012. doi: 10.1016/j.diabres.2012.09.003
  49. 49.
    Rafiq S, Melzer D, Weedon MN, et al. Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. Diabetologia. 2008;51:2205–13.PubMedCrossRefGoogle Scholar
  50. 50.
    Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44:981–90.PubMedCrossRefGoogle Scholar
  51. 51.
    Volkmar M, Dedeurwaerder S, Cunha DA, et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J. 2012;31:1405–26.PubMedCrossRefGoogle Scholar
  52. 52.
    Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol. 2010;299:F14–25.PubMedCrossRefGoogle Scholar
  53. 53.
    Gilbert ER, Liu D. Epigenetics: the missing link to understanding beta-cell dysfunction in the pathogenesis of type 2 diabetes. Epigenetics. 2012;7:841–52.PubMedCrossRefGoogle Scholar
  54. 54.
    •• Gkrania-Klotsas E, Ye Z, Cooper AJ, et al. Differential white blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studies. PLoS One. 2010;5:e13405. This systematic review and meta-analysis based on a large number of studies and participants provides evidence supporting the association of total white cell counts and subfractions on type 2 diabetes risk.PubMedCrossRefGoogle Scholar
  55. 55.
    Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl. 2012;6:91–101.PubMedCrossRefGoogle Scholar
  56. 56.
    Otero M, Lago R, Lago F, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005;579:295–301.PubMedCrossRefGoogle Scholar
  57. 57.
    Maya-Monteiro CM, Bozza PT. Leptin and mTOR: partners in metabolism and inflammation. Cell Cycle. 2008;7:1713–7.PubMedCrossRefGoogle Scholar
  58. 58.
    La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4:371–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Thorand B, Zierer A, Baumert J, et al. Associations between leptin and the leptin / adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA / KORA Augsburg study 1984–2002. Diabet Med. 2010;27:1004–11.PubMedCrossRefGoogle Scholar
  60. 60.
    Welsh P, Murray HM, Buckley BM, et al. Leptin predicts diabetes but not cardiovascular disease: results from a large prospective study in an elderly population. Diabetes Care. 2009;32:308–10.PubMedCrossRefGoogle Scholar
  61. 61.
    Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285:E527–33.PubMedGoogle Scholar
  62. 62.
    Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323:630–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Sell H, Eckel J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? Proc Nutr Soc. 2009;68:378–84.PubMedCrossRefGoogle Scholar
  64. 64.
    Roman AA, Parlee SD, Sinal CJ. Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine. 2012;42:243–51.PubMedCrossRefGoogle Scholar
  65. 65.
    Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev. 2013;14:245–62.Google Scholar
  66. 66.
    Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.PubMedCrossRefGoogle Scholar
  67. 67.
    Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003;14:137–45.PubMedCrossRefGoogle Scholar
  68. 68.
    Fasshauer M, Paschke R. Regulation of adipocytokines and insulinresistance. Diabetologia. 2003;46:1594–603.PubMedCrossRefGoogle Scholar
  69. 69.
    Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23:1042–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes. 2002;51:3176–88.PubMedCrossRefGoogle Scholar
  71. 71.
    Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245:621–5.PubMedCrossRefGoogle Scholar
  72. 72.
    Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001;9:414–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Pradhan A, Manson J, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34.PubMedCrossRefGoogle Scholar
  74. 74.
    Ye J, McGuinness OP. Inflammation during obesity is not all bad: Evidence from animal and human studies. Am J Physiol Endocrinol Metab. 2013;304:E466–77.Google Scholar
  75. 75.
    Luotola K, Pietila A, Zeller T, et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. J Intern Med. 2011;269:322–32.PubMedCrossRefGoogle Scholar
  76. 76.
    Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia. 2008;51:926–40.PubMedCrossRefGoogle Scholar
  77. 77.
    Xu JW, Morita I, Ikeda K, et al. C-reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol Endocrinol. 2007;21:564–73.PubMedCrossRefGoogle Scholar
  78. 78.
    Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance–a mini-review. Gerontology. 2009;55:379–86.PubMedCrossRefGoogle Scholar
  79. 79.
    Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–35.PubMedCrossRefGoogle Scholar
  80. 80.
    •• Tanti JF, Ceppo F, Jager J, Berthou F. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front Endocrinol. 2012;3:181. This paper provides an extensive and recent overview on signaling pathways linking obesity to insulin resistance.Google Scholar
  81. 81.
    Haruta T, Uno T, Kawahara J, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000;14:783–94.PubMedCrossRefGoogle Scholar
  82. 82.
    Hiratani K, Haruta T, Tani A, et al. Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1. Biochem Biophys Res Commun. 2005;335:836–42.PubMedCrossRefGoogle Scholar
  83. 83.
    Lebrun P, Van Obberghen E. SOCS proteins causing trouble in insulin action. Acta Physiol. 2008;192:29–36.CrossRefGoogle Scholar
  84. 84.
    Hirabara SM, Gorjao R, Vinolo MA, et al. Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol. 2012;2012:379024.PubMedCrossRefGoogle Scholar
  85. 85.
    Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54:1566–72.PubMedCrossRefGoogle Scholar
  86. 86.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar
  87. 87.
    Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152:346–57.PubMedCrossRefGoogle Scholar
  88. 88.
    Rumore MM, Kim KS. Potential role of salicylates in type 2 diabetes. Ann Pharmacother. 2010;44:1207–21.PubMedCrossRefGoogle Scholar
  89. 89.
    Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597–605.PubMedCrossRefGoogle Scholar
  90. 90.
    Bernstein LE, Berry J, Kim S, et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006;166:902–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005;42:517–25.PubMedCrossRefGoogle Scholar
  92. 92.
    Pittas AG, Chung M, Trikalinos T, et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152:307–14.PubMedCrossRefGoogle Scholar
  93. 93.
    • George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med. 2012;29:e142–50. This systematic review and meta-analysis showed that vitamin D supplementation had a small improvement effect on fasting glucose and insulin resistance among people with diabetes or impaired glucose tolerance, but no effect on glycated haemoglobin among those with diabetes.PubMedCrossRefGoogle Scholar
  94. 94.
    Panwar H, Rashmi HM, Batish VK, Grover S. Probiotics as the potential biotherapeutics in the management of Type 2 Diabetes—prospects and perspectives. Diabetes Metab Res Rev. 2013;29:103–12.Google Scholar
  95. 95.
    Zhao Y, Jiang Z, Guo C. New hope for type 2 diabetics: targeting insulin resistance through the immune modulation of stem cells. Autoimmun Rev. 2011;11:137–42.PubMedCrossRefGoogle Scholar
  96. 96.
    Kengne AP, Sobngwi E, Chalmers J. Multiple risk factor interventions and inflammatory biomarkers in high risk individuals with type 2 diabetes. Diabetes Res Clin Pract. 2012;95:386–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Eric Lontchi-Yimagou
    • 1
  • Eugene Sobngwi
    • 2
    • 3
  • Tandi E. Matsha
    • 4
  • Andre Pascal Kengne
    • 5
    • 6
    • 7
    Email author
  1. 1.Laboratory for Molecular and Metabolic Diseases, Biotechnology CenterUniversity of Yaoundé 1YaoundéCameroon
  2. 2.National Obesity CenterYaounde Central Hospital and Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1YaoundéCameroon
  3. 3.Institute of Health and SocietyNewcastle UniversityNewcastleUK
  4. 4.Department of Biomedical Sciences, Faculty of Health and Wellness ScienceCape Peninsula University of TechnologyCape TownSouth Africa
  5. 5.South African Medical Research Council & University of Cape TownCape TownSouth Africa
  6. 6.The George Institute for Global HealthSydneyAustralia
  7. 7.Julius Center for Health Sciences and Primary CareUniversity Medical Center UtrechtUtrechtThe Netherlands

Personalised recommendations